文献速递重症综合管理与镇静镇痛

氟哌啶醇对谵妄高风险危重症成人存活率的影响:REDUCE随机临床试验

Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在谵妄高风险危重症成人中,预防性使用氟哌啶醇与安慰剂相比未改善28天生存,作者认为这些发现不支持用预防性氟哌啶醇降低危重症成人死亡率。

该随机、双盲、安慰剂对照研究在荷兰21个ICU纳入1789例无谵妄且预期ICU停留至少1天的危重症成人,比较预防性氟哌啶醇1 mg或2 mg每日3次静脉给药与安慰剂(0.9%氯化钠)。1 mg组因无效提前终止。2 mg组与安慰剂组28天内生存天数中位数均为28天,差异0天(95%CI 0-0,P=.93),风险比1.003(95%CI 0.78-1.30,P=.82)。15项次要结局均无统计学差异,包括谵妄发生率(平均差异1.5%,95%CI -3.6%至6.7%)。作者结论认为这些发现不支持用预防性氟哌啶醇降低危重症成人死亡率。

要点

  • 在谵妄高风险(预期ICU停留至少2天)危重症成人中,预防性氟哌啶醇2 mg每日3次静脉给药与安慰剂相比,28天内生存天数中位数均为28天,差异0天(95%CI 0-0,P=.93)。
  • 2 mg氟哌啶醇组与安慰剂组风险比为1.003(95%CI 0.78-1.30,P=.82),28天生存无差异。
  • 15项次要结局均无统计学差异,包括谵妄发生率(平均差异1.5%,95%CI -3.6%至6.7%)及谵妄无昏迷天数(平均差异0天,95%CI 0-0天)。
  • 1 mg氟哌啶醇组因无效提前终止。
  • 作者结论认为这些发现不支持用预防性氟哌啶醇降低危重症成人死亡率。

适用人群与场景

  • 荷兰21个ICU中无谵妄且预期ICU停留至少1天的危重症成人,常规使用非药物干预预防谵妄。
  • 研究纳入标准为预期ICU停留至少2天定义为谵妄高风险;实际纳入患者无谵妄且预期ICU停留至少1天。

处置流程与药物剂量

  • 预防性治疗每日3次静脉给药:氟哌啶醇1 mg(n=350)或2 mg(n=732),或安慰剂(0.9%氯化钠,n=707)。
  • 1 mg氟哌啶醇组因无效提前终止。

研究设计与关键结果

  • 随机、双盲、安慰剂对照、研究者驱动研究,纳入1789例危重症成人,来自21个ICU,平均年龄66.6岁(SD 12.6),男性1099例(61.4%)。
  • 主要结局28天内生存天数:2 mg氟哌啶醇组中位数28天 vs 安慰剂组28天,差异0天(95%CI 0-0,P=.93),风险比1.003(95%CI 0.78-1.30,P=.82)。
  • 15项次要结局均无统计学差异:谵妄发生率平均差异1.5%(95%CI -3.6%至6.7%),谵妄无昏迷天数平均差异0天(95%CI 0-0天),机械通气时长、ICU住院时长和医院住院时长平均差异均为0天(95%CI 0-0天)。
  • 不良事件报告数两组无差异:2 mg氟哌啶醇组2例(0.3%) vs 安慰剂组1例(0.1%)。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在谵妄高风险危重症成人中,预防性使用氟哌啶醇与安慰剂相比未改善28天生存,这些发现不支持用预防性氟哌啶醇降低危重症成人死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium.

OBJECTIVE: To determine whether prophylactic use of haloperidol improves survival among critically ill adults at high risk of delirium, which was defined as an anticipated intensive care unit (ICU) stay of at least 2 days.

DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled investigator-driven study involving 1789 critically ill adults treated at 21 ICUs, at which nonpharmacological interventions for delirium prevention are routinely used in the Netherlands. Patients without delirium whose expected ICU stay was at least a day were included. Recruitment was from July 2013 to December 2016 and follow-up was conducted at 90 days with the final follow-up on March 1, 2017.

INTERVENTIONS: Patients received prophylactic treatment 3 times daily intravenously either 1 mg (n = 350) or 2 mg (n = 732) of haloperidol or placebo (n = 707), consisting of 0.9% sodium chloride.

MAIN OUTCOME AND MEASURES: The primary outcome was the number of days that patients survived in 28 days. There were 15 secondary outcomes, including delirium incidence, 28-day delirium-free and coma-free days, duration of mechanical ventilation, and ICU and hospital length of stay.

RESULTS: All 1789 randomized patients (mean, age 66.6 years [SD, 12.6]; 1099 men [61.4%]) completed the study. The 1-mg haloperidol group was prematurely stopped because of futility. There was no difference in the median days patients survived in 28 days, 28 days in the 2-mg haloperidol group vs 28 days in the placebo group, for a difference of 0 days (95% CI, 0-0; P = .93) and a hazard ratio of 1.003 (95% CI, 0.78-1.30, P=.82). All of the 15 secondary outcomes were not statistically different. These included delirium incidence (mean difference, 1.5%, 95% CI, -3.6% to 6.7%), delirium-free and coma-free days (mean difference, 0 days, 95% CI, 0-0 days), and duration of mechanical ventilation, ICU, and hospital length of stay (mean difference, 0 days, 95% CI, 0-0 days for all 3 measures). The number of reported adverse effects did not differ between groups (2 [0.3%] for the 2-mg haloperidol group vs 1 [0.1%] for the placebo group).

CONCLUSIONS AND RELEVANCE: Among critically ill adults at high risk of delirium, the use of prophylactic haloperidol compared with placebo did not improve survival at 28 days. These findings do not support the use of prophylactic haloperidol for reducing mortality in critically ill adults.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01785290.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. van den Boogaard M, Slooter AJC, Brüggemann RJM, et al. Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. JAMA. 2018. PMID: 29466591. doi:10.1001/jama.2018.0160

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。